Overview

Dose-response Study of OPC-12759 Ophthalmic Suspension

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Rebamipide